|
Genmab Announces Update On AMG 714 Program With Amgen |
|
|
|
11 Mar 2006 |
COPENHAGEN, Denmark | Mar 10, 2006 | Genmab A/S (CSE: GEN) announced today that Amgen has announced in its Form 10-K for 2005 an update on the development status of AMG 714 (formerly referred to as HuMax-IL15), a fully human antibody directed against interleukin-15 (IL-15) that is being developed under an agreement with Genmab. Amgen has reformulated AMG 714 in a more commercially productive cell line and the antibody is undergoing preclinical testing. The company anticipates entering a Phase I study with the new formulation in 2006.
A Phase II trial investigating AMG 714 in the treatment of rheumatoid arthritis has been completed and the data is expected to be presented later this year.
IL-15 blockade has potential utility in a wide variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, lupus, multiple sclerosis, and others.
SOURCE: Genmab A/S |
